Last reviewed · How we verify
In open-label phase: treatment with tofacitinib (in-open-label-phase-treatment-with-tofacitinib)
Tofacitinib is a medication used to treat various inflammatory conditions. Developed by Pfizer Inc., it is a marketed drug. The exact mechanism of tofacitinib is not fully understood, but it is believed to work by inhibiting the activity of certain enzymes in the body. Tofacitinib is used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It has been shown to be effective in reducing symptoms and improving quality of life for patients with these conditions. However, it can have side effects and may not be suitable for everyone. Overall, tofacitinib is a significant addition to the treatment options available for inflammatory conditions.
At a glance
| Generic name | in-open-label-phase-treatment-with-tofacitinib |
|---|---|
| Sponsor | Pfizer |
| Drug class | Janus kinase inhibitor |
| Target | Janus kinase 1 (JAK1), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2) |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| Annual revenue | 1087 |
Approved indications
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Polyarticular Juvenile Idiopathic Arthritis
- Ulcerative Colitis
- Psoriasis
- Atopic Dermatitis
Common side effects
Drug interactions
- Warfarin
- Rivaroxaban
- Apixaban
- Dabigatran
- Pantoprazole
- Ketoconazole
- Rifampicin
- Phenobarbital
- Carbamazepine
- Phenytoin
- St. John's Wort
- CYP3A4 inducers
Key clinical trials
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease (PHASE2)
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) (PHASE4)
- A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA (PHASE3)
- A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis (PHASE3)
- Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare (PHASE1)
- Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease (PHASE4)
- A Study of JNJ-64251330 in Healthy Participants (PHASE1)
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: